Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H29N3O6 |
Molecular Weight | 491.5357 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)O[C@H]3CCN(CC4=CC=CC=C4)C3
InChI
InChIKey=VXMOONUMYLCFJD-DHLKQENFSA-N
InChI=1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1
Molecular Formula | C27H29N3O6 |
Molecular Weight | 491.5357 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/?term=11434453
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=11434453
Bamidipine is an antihypertensive drug belonging to the dihydropyridine (DHP) group of calcium antagonists. The product was originally developed by Yamanouchi Pharmaceutical (Tokyo, Japan) and is currently marketed in Japan under the trade name of Hypoca (Astellas Pharma Inc, Tokyo, Japan). It is available in a modified-release formulation which has a gradual onset of action and is effective in a single daily oral dose of 10 to 20 mg. Bamidipine has selective action against cardiovascular calcium antagonist receptors and its antihypertensive action is related to the reduction of peripheral vascular resistance secondary to its vasodilatory action. The clinical antihypertensive efficacy of barnidipine is similar to that of other DHP calcium antagonists such as nitrendipine and amlodipine, and antihypertensives belonging to other drug classes such as atenolol and enalapril. Barnidipine has been found to be as efficacious and well tolerated as hydrochlorothiazide in the management of hypertension in elderly patients. Barnidipine is generally well tolerated. As with other DHP calcium antagonists, vasodilator adverse events such as headache, flushing and peripheral oedema account for most of the adverse events reported with its use and are usually transient. Oedema is less frequent than with amlodipine and nitrendipine. Its use is not associated with reflex tachycardia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363032 Sources: http://www.ncbi.nlm.nih.gov/pubmed/15853594 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=11434453
single daily oral dose of 10 to 20 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 20:52:52 UTC 2022
by
admin
on
Sun Dec 18 20:52:52 UTC 2022
|
Record UNII |
2VBY96ASWJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08CA12
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
||
|
WHO-ATC |
C08CA12
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39879
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | RxNorm | ||
|
2VBY96ASWJ
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
SUB06105MIG
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
6746
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
CHEMBL2103761
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
C73024
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
DB09227
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
M2268
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | Merck Index | ||
|
BARNIDIPINE
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
C050699
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
104713-75-9
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
DTXSID20909147
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
290
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY | |||
|
443869
Created by
admin on Sun Dec 18 20:52:53 UTC 2022 , Edited by admin on Sun Dec 18 20:52:53 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |